Richard M. Tjon Joe Gin

TL;DR: In patients undergoing primary PCI, a CYP2C19 genotype-guided strategy for selection of oral P2Y12 inhibitor therapy was noninferior to standard treatment with ticagrelor or prasugrel at 12 months with respect to thrombotic events and resulted in a lower incidence of bleeding.

TL;DR: In this article, a prespecified subanalysis of the POPULAR Genetics trial was performed, using patients in whom CYP2C19*2, *3, and *17 genotypes was determined.

TL;DR: In this article, the authors evaluated the cost effectiveness of a genotype-guided P2Y12 inhibitor strategy compared with standard treatment with ticagrelor or prasugrel without increasing thrombotic event rates after primary percutaneous coronary intervention (PCI).

TL;DR: In ACS patients aged 70 years and older, there was no significant difference in net clinical benefit and atherothrombotic outcomes between noncarriers of a loss-of-function allele treated with clopidogrel and patients treated with ticagrelor.